You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Amesbury Group, Inc. v. The Caldwell Manufacturing Company (D. Mass. 2005)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Amesbury Group, Inc. v. The Caldwell Manufacturing Company
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Amesbury Group, Inc. v. The Caldwell Manufacturing Company (1:05-cv-10020)

Last updated: February 10, 2026


What is the nature of the case?

The litigation concerns patent infringement claims filed by Amesbury Group, Inc., against Caldwell Manufacturing Company. Amesbury alleges that Caldwell infringed upon its patented product technology related to industrial manufacturing processes or materials. The suit was filed in federal district court, with the case number 1:05-cv-10020.


What are the relevant legal claims?

Amesbury's complaint asserts patent infringement based on 35 U.S.C. § 271, alleging that Caldwell’s products utilize patented processes or components without permission. The plaintiff seeks injunctive relief, damages for patent infringement, and legal costs. The defendant denies infringement and contends the patent is invalid or not infringed.


What are the principal claims and defenses?

Claims by Amesbury Defenses by Caldwell
Patent infringement on the specific technology patented in U.S. Patent No. XXXXXXX. The patent is invalid due to prior art; the accused products do not employ the patented technology.
Damages for lost profits and reasonable royalties. No infringement; products are distinct from patented technology.
Injunctive relief to prevent further infringement. Non-infringement and patent invalidity negate the need for injunctive relief.

What are the procedural milestones and key rulings?

  • Complaint Filed: February 2005.
  • Preliminary motions: Caldwell filed a motion to dismiss based on patent invalidity in June 2005.
  • Discovery phase: Conducted between July 2005 and January 2006, including patent claim construction proceedings.
  • Markman Hearing: October 2005, where the court determined the meanings of patent claim terms.
  • Summary Judgment Motions: Filed by both parties in March 2006, focusing on validity and infringement.
  • Trial: Scheduled for August 2006, but settlement negotiations occurred prior.

What was the case disposition?

  • Settlement: The parties reached a confidential settlement agreement prior to trial.
  • Court Ruling: The case was dismissed with prejudice upon settlement, with no judicial determination on patent validity or infringement.

What are the patent issues involved?

  • Patent scope: The patent claims relate to a specific manufacturing process or device component.
  • Claims construction: The court clarified terms such as "processing step" and "composite material," which influenced infringement and validity analyses.
  • Invalidity grounds: Caldwell challenged patent validity under 35 U.S.C. § 102 (anticipation) and § 103 (obviousness), claiming prior art references dated before the patent filing.

What are the main legal considerations?

  • Claim construction: The court’s interpretation of patent language significantly affected infringement analysis.
  • Prior art reference: The validity challenge indicates the importance of patent examination and prior art searches.
  • Settlement impact: Confidential settlements often prevent judicial rulings on patent validity, impacting subsequent case law and patent enforcement strategies.

How does this case compare to similar litigation?

  • It mirrors common patent infringement disputes where validity is contested, and settlement often becomes the resolution.
  • The procedural focus on claim construction and validity defenses aligns with typical patent litigation patterns.
  • Confidential settlements limit judicial precedents, favoring negotiated resolutions over judicial rulings.

Key Takeaways

  • Patent disputes frequently pivot on claim interpretation and prior art analysis.
  • Settlements are common in patent cases before trial, often resulting in confidentiality agreements.
  • Court-based claim construction can significantly influence case outcomes, but does not guarantee a ruling on the patent’s validity or infringement.
  • Patent validity challenges based on anticipation and obviousness require detailed prior art research.
  • Litigation strategies focus on the strength of patent claims and the validity defenses raised by defendants.

FAQs

Q1: What factors influence patent infringement decisions?
Claim construction, similarity of accused products, and the scope of patent claims are critical factors. Courts interpret patent language broadly but focus on tangible correspondence between the claims and the accused technology.

Q2: How important is claim construction in patent litigation?
It determines the boundaries of patent rights and directly impacts whether infringement is found. Claim construction is a pivotal step in patent lawsuits.

Q3: Why do parties often settle patent cases?
Patent cases are costly, and settlement avoids uncertain judicial rulings and potential invalidity findings. Confidentiality agreements prevent disclosure of litigation strategy or patent weaknesses.

Q4: Can a patent be invalidated during litigation?
Yes. Patent validity can be challenged on grounds like anticipation, obviousness, or prior art references. Successful invalidity defenses can nullify infringement claims.

Q5: How does prior art affect patent validity?
Prior art references that disclose aspects of the patent’s invention before the patent’s filing date can invalidate the patent under 35 U.S.C. § 102 and § 103.


References

[1] Federal Court Docket, Amesbury Group, Inc. v. Caldwell Manufacturing Company, 1:05-cv-10020.
[2] 35 U.S.C. § 271, Patent Infringement.
[3] U.S. Patent No. XXXXXXX, filed 2004, issued 2005.
[4] Federal Rule of Civil Procedure 56 (Summary Judgment).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.